Compare Magna International Inc. Common Stock (MGA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magna International Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Magna International Inc. Common Stock trades at $64.38 (market cap $17.25B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Magna International Inc. Common Stock is far larger — about 4.8× Organon & Co. Common Stock's market cap, and Magna International Inc. Common Stock pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| MGA | OGN | |
|---|---|---|
Market Cap | $17.25B | $3.61B |
Volume | 894,575 | 1,808,049 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $13.81 |
52-Week Low | $44.65 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.29B | $11.03B |
Dividend Yield | 3.07% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magna International (MGA) trades at $65.31, up 2.75% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and trades at attractive valuations with P/E of 24.01 and P/S of 0.43. Recent news highlights margin expansion and international growth opportunities, while cash flow remains positive despite increased capital returns.
MGA presents a favorable risk-reward profile with analyst consensus target of $69.20 (5.9% upside) and 43% buy ratings. Key catalysts include Q3 2026 earnings on October 30 and continued margin improvement, though risks include flat auto production and potential tariff impacts on North American operations.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Magna International Inc. Common Stock
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
